Figure 3.
ASC protein aggregates and proinflammatory cytokines measured in the serum obtained from 2 control groups and the Schnitzler syndrome patients prior to their treatment with anakinra. (A) Extracellular ASC specks per microliter in the serum from HCs (n = 11), patients with Schnitzler syndrome (n = 17), and CAPS (n = 7). Significant difference was observed between HCs and Schnitzler syndrome (**P = .0151) and between HC and CAPS (*P = .0304). (B) IL-18 levels in HCs (n = 21), patients with Schnitzler syndrome (n = 17), and CAPS (n = 7). Significant difference was observed between HCs and Schnitzler syndrome (****P < .0001) and between HC and CAPS patients (***P = .0003). (C) IL-6 levels in HC (n = 12), patients with Schnitzler syndrome (n = 17), and CAPS (n = 7). Significant difference was observed between HCs and Schnitzler syndrome (***P = .0005) and between HCs and CAPS (**P = .0016) patients. No significant difference of ASC protein aggregates, IL-18, and IL-6 was observed between the Schnitzler syndrome and CAPS cohorts. The Kruskal-Wallis 1-way ANOVA test was used to derive significances between the nonparametric data obtained. P values ≤ .05 were regarded as significant. SchS, Schnitzler syndrome.